Locations:
Cleveland Clinic Cancer Institute takes multi-faceted approach to ensuring clinical trials representation
Key learnings from DESTINY trials
Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients
Two-year event-free survival comparable to matched sibling donor myeloablative transplant
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors
First-in-human trials of CRISPR-Cas12a gene editing demonstrate safety and meaningful event-free survival
Improvements enable targeting of brain tumors with single-session, fractionated or neoadjuvant approaches
Study of 401,576 patients reveals differences in cancer burdens as well as overall survival
Consult program a valuable tool that benefits both patients and clinicians
Additional fine-tuning and recruiting of new patient groups underway
Advertisement
Advertisement
Search